跳至主要内容
临床试验/NCT02913183
NCT02913183Unknown2 期

Efficacy and Safety of Young Health Plasma on Acute Stroke

Xinqiao Hospital of Chongqing0 个研究点目标入组 78 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
78
主要终点
Changes in modified Barthel Index

研究概览

简要总结

Stroke is one of the main severe disease of public health importance. Recent studies showed that old age is one of the most important factors in influencing the outcome of patients with acute stroke, and the young plasma can reverse age-related brain impairments in mice. Therefore, this pilot study aims to investigate whether young plasma is effective in alleviating brain injury and neurologic deficits induced by acute stroke in patients.

详细描述

This study will enroll 78 stroke patients who have been diagnosed with stroke and meet the inclusion criteria.

After successfully meeting initial screening criteria, investigators will contact the family, explain the study, and send a consent form for their review.

After that, patients will be given 2 unit/day young health plasma (young plasma exchange) over a course of 3 consecutive days, then investigators will make a neurofunctional assessment before and 7 days, 30 days and 90 days after young health plasma treatment. And Magnetic Resonance of the brain before, 7 days, 14 days and 90 days after young health plasma treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
65 Years 至 80 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 65-80 years
  • Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke
  • CT/MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke
  • Time to young plasma treatment < 72 h from symptom onset
  • Glasgow Coma Score > 6 on initial presentation or improvement to a Glasgow Coma Score > 6 within the time frame for enrollment
  • The first-ever primary supratentorial intracerebral basal ganglia hemorrhage 5-30ml
  • Signed and dated informed consent is obtained
  • TOAST: Large-artery atherosclerosis

排除标准

  • Patients who will undergo surgical evacuation of intracerebral hemorrhage/ischemic stroke
  • Inability to undergo neuroimaging with Magnetic Resonance
  • Glasgow Coma Score < 6
  • Significant past history of disability, modified Rankin Scale(mRS)≥1
  • Primary intraventricular hemorrhage ICH due to coagulopathy (PT > 15 s or International Normalized Ratio > 1.3, Partial Thromboplastin Time > 36) or trauma
  • Thrombocytopenia: platelet count <100 000
  • Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs >2x normal, coagulopathy as described)
  • Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome
  • Known pregnancy, or positive pregnancy test, or breast feeding
  • Malignancy (history of or active)
  • Bradyarrhythmia and Atrioventricular Block
  • Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies
  • Macular Edema
  • Life expectancy of less than 90 days due to comorbid conditions
  • Occurrences of secondary intracerebral hemorrhage/ischemic stroke
  • Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause

研究组 & 干预措施

young Fresh Frozen Plasma

Experimental
  1. Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.
  2. Drug: young plasma exchange over a course of 3 consecutive days after stroke onset.

干预措施: young Fresh Frozen Plasma (Drug)

old Fresh Frozen Plasma

Placebo Comparator
  1. Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.
  2. Old plasma exchange over a course of 3 consecutive days after stroke onset.
  3. Patients will receive usual care and drug use in hospital.

干预措施: old Fresh Frozen Plasma (Drug)

结局指标

主要结局

Changes in modified Barthel Index

时间窗: up to 90 days

describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days

Changes in Glasgow coma scale

时间窗: up to 90 days

describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days

Changes in National Institutes of Health Stroke Scale (NIHSS)

时间窗: up to 90 days

describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days

Changes in modified Rankin Scale

时间窗: up to 90 days

describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days

次要结局

  • Change in peripheral edema volume(At baseline, 7 days, 14 days and 30 days after the onset)
  • Changes in hematoma volume(At baseline, 7 days, 14 days and 30 days after the onset)

研究者

发起方
Xinqiao Hospital of Chongqing
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiao-Yi Xiong

Medical Doctor

Xinqiao Hospital of Chongqing

相似试验